All News

Patients with newly diagnosed multiple myeloma experienced rapid responses and notable rates of minimal residual disease negativity following minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer.

Adjuvant atezolizumab led to disease-free survival benefit in patients with early-stage non–small cell lung cancer, including most patient subgroups, in the phase 3 IMpower010 trial.

Patients with relapsed/refractory multiple myeloma who were treated with the recommended phase 2 dose of talquetamab experienced positive clinical activity.

Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.

Continued efficacy of CAR T-cell therapy with idecabtagene vicleucel in patients with pretreated myeloma is evidenced by updated KarMMa trial findings presented at the 18th International Myeloma Workshop.

The combination of melflufen plus dexamethasone produced a progression-free survival benefit over pomalidomide plus dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma.

Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.

A population of patients with relapsed/refractory multiple myeloma who received elranatamab with or without lenalidomide experienced encouraging responses despite being heavily pretreated.

Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.

Epcoritamab monotherapy yielded positive results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and should be studied further, according to investigators.

Ciltacabtagene autoleucel may provide patients with myeloma who have developed progressive disease a more long-term treatment option.

Strategies from the COVID-19 pandemic such as flexible, patient-focused approaches and telehealth may work to increase enrollment on clinical lung cancer trials by increasing accessibility.

Minimal residual disease negativity may predict outcomes for patients with multiple myeloma on maintenance therapy with lenalidomide who previously underwent autologous stem cell transplantation.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.

The NovoTTF-200T System was given a breakthrough designation by the FDA as treatment strategy that may work in conjunction with bevacizumab and atezolizumab to treat patients with advanced liver cancer.

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.

Findings from a phase 1/2 study indicated that patients with relapsed/refractory multiple myeloma who were treated with iberdomide plus dexamethasone and daratumumab/bortezomib or carfilzombib experienced promising efficacy and tolerable safety.

Patients with multiple myeloma with standard or high-risk cytogenic abnormalities who were treated with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant experienced promising responses.

Updated results confirmed the safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with no immediate intent for transplant.

The combination of daratumumab plus lenalidomide and dexamethasone demonstrated a significant overall survival benefit compared with lenalidomide and dexamethasone alone for patients with newly diagnosed multiple myeloma.

The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.

The use of onvansertib in combination with standard-of-care chemotherapy had an increase in the objective response rate and progression-free survival during the phase 1b/2 trial for metastatic colorectal cancer.

Patients with EGFR-mutated non–small cell lung cancer who were treated with ado-trastuzumab emtansine and osimertinib experienced minimal anti-tumor outcomes.

Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.

The anti-PD-1 antibody spartalizumab demonstrated promising responses in patients with recurrent/metastatic nasopharyngeal cancer.

In the early days of the COVID-19 pandemic, patients with malignant pleural mesothelioma were more likely to be hospitalized or die from COVID-19 versus the overall population.

Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.